RxDoctor Payments Data

T White, MD

Interventional Cardiology · Fort Wayne, INNPI 1235121104

Payments from drug & device makers

$5,516in general payments, 2019–2025

Across 142 payments — averaging $38.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Johnson & Johnson$1K
  • Medtronic$741
  • E.r. Squibb & Sons, L.L.C.$306
  • Edwards Lifesciences$255
  • Boehringer Ingelheim$197
  • plus $786 from 12 others

What the payments were for

  • Travel & lodging$1,73731%
  • Food & beverage$3,75868%
  • Education$210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,516 in reported general payments places this provider in the 40th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$146,542
Medicare patients
606
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$347,023
XareltoRivaroxaban260$312,358
Repatha SureclickEvolocumab102$85,313
MultaqDronedarone Hcl20$31,061
EntrestoSacubitril/Valsartan18$29,113
Metoprolol Succinate539$5,675
Amiodarone Hcl129$5,598
Atorvastatin Calcium658$4,758
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,614
ClopidogrelClopidogrel Bisulfate348$3,338
Diltiazem 24hr Er (Cd)Diltiazem Hcl134$3,331
Ezetimibe149$3,084
Rosuvastatin Calcium194$2,264
Nitroglycerin169$2,138
Losartan Potassium236$1,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$347,023319 claims
Johnson & JohnsonXarelto$1,091$312,358260 claims
Sanofi-aventis U.S. LLCMultaq$23$31,06120 claims
NovartisEntresto$113$29,11318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →